Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Invested Capital (2021 - 2025)

ARS Pharmaceuticals' Invested Capital history spans 5 years, with the latest figure at $214.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 16.57% year-over-year to $214.3 million; the TTM value through Dec 2025 reached $214.3 million, down 16.57%, while the annual FY2025 figure was $214.3 million, 16.57% down from the prior year.
  • Invested Capital for Q4 2025 was $214.3 million at ARS Pharmaceuticals, down from $243.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at $369.0 million in Q1 2021 and bottomed at -$50.2 million in Q3 2022.
  • The 5-year median for Invested Capital is $229.9 million (2023), against an average of $195.7 million.
  • The largest YoY upside for Invested Capital was 972.7% in 2022 against a maximum downside of 115.1% in 2022.
  • A 5-year view of Invested Capital shows it stood at -$31.3 million in 2021, then soared by 972.7% to $272.9 million in 2022, then decreased by 15.44% to $230.8 million in 2023, then rose by 11.28% to $256.8 million in 2024, then fell by 16.57% to $214.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Invested Capital are $214.3 million (Q4 2025), $243.9 million (Q3 2025), and $192.3 million (Q2 2025).